Login

H. Dai

ORCID: 0000-0002-3576-5121
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5007468819
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • MRI in cancer diagnosis
  • Bladder and Urothelial Cancer Treatments
  • Radiomics and Machine Learning in Medical Imaging
  • CAR-T cell therapy research
  • Colorectal Cancer Treatments and Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Monoclonal and Polyclonal Antibodies Research
  • Lung Cancer Treatments and Mutations
  • Cancer Research and Treatments
  • Lung Cancer Research Studies

Fujian Medical University
 2024

First Affiliated Hospital of Fujian Medical University
 2024

Roche (China)
 2016

 A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma
OPENALEX - Publications 
H. Dai Chuan Yan Wanrong Huang Yifan Pan Feng Pan and 5 more Yamei Liu Shunli Wang Huifang Wang Rongping Ye Yueming Li

Backgrounds Anti‐vascular endothelial growth factor (VEGF) therapy has been developed and recognized as an effective treatment for hepatocellular carcinoma (HCC). However, there remains a lack of noninvasive methods in precisely evaluating VEGF expression HCC. Purpose To establish visual model based on clinical indicators MRI features to evaluate Study Type Retrospective. Population One hundred forty HCC patients were randomly divided into training (N = 98) test cohort 42). Field...

10.1002/jmri.29491 article EN cc-by-nc-nd Journal of Magnetic Resonance Imaging 2024-06-22
 1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study
OPENALEX - Publications 
Lin Shen J. Li Z. Miao Nong Xu B. Liu and 12 more X. Li Q. Zhang Quanli Gao Yanqiu Zhao Hongming Pan Zhi‐Jun Pei W. Li Haoran Xia J. Wang H. Dai Qin Shi H. J. Yang

10.1016/j.annonc.2020.08.1951 article EN publisher-specific-oa Annals of Oncology 2020-09-01
 A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas
OPENALEX - Publications 
Lin Shen J. Li Nong Xu Baocai Xing Q. Zhang and 6 more Yanqiu Zhao Junning Cao J. Ding J. Wang Y. Wang H. Dai

10.1093/annonc/mdz253.093 article EN publisher-specific-oa Annals of Oncology 2019-10-01
 1984P Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial
OPENALEX - Publications 
Chao Yang H. Huang Xianlu Zeng H. Dai Guohua Zhou and 2 more S. Wang Zhiquan Hu

10.1016/j.annonc.2024.08.2069 article EN Annals of Oncology 2024-09-01
 59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening
OPENALEX - Publications 
X.-C. Zhang Chongqi Sun Z. Xie Xin Cao Jìng Guo and 10 more Jin‐Ji Yang Xue‐Ning Yang H. Dai J. Lee Yuanhao Zuo M. Chen Astrid Kiermaier D. Shames Georgina Cheng Yi‐Long Wu

10.1016/s0923-7534(21)00220-9 article EN publisher-specific-oa Annals of Oncology 2016-12-01
 516 Chimeric Antigen Receptor-Modified T Cells for the immunotherapy of patients with Her-1 expressing advanced relapsed/refractory Non-Small Cell Lung Cancer
OPENALEX - Publications 
Keyi Feng Yu Guo H. Dai Yi Wang Shibo Li and 8 more Qiuli Yang M.-X. Chen Y. Zhang Y.-J. Zhang C.-M. Wang W.-Y. Zhang Xiangming Li Weili Han

10.1016/s0959-8049(16)30317-3 article EN European Journal of Cancer 2015-09-01
Coming Soon ...